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Background: Anhedonia, the lowered ability to experience pleasure, is one of the non-
motor symptoms of Parkinson’s disease (PD) that is underdiagnosed and consequently
undertreated. Few studies have investigated anhedonia in PD by taking into account the
influence of socio-demographic variables and versus a control group composed of patients
with a pure motor neurologic disease other than PD. The aim of this study was to inves-
tigate hedonic deficits in patients with PD compared to a control group of patients with
non-Parkinson motor neurologic disease (OND), matched for age, gender, level of educa-
tion, and inpatient/outpatient status. Distinctions between anticipatory and consummatory
anhedonia and between endogenomorphic and non-endogenomorphic depression were
taken into account.
Methods:The study population comprised 49 PD patients and 40 subjects with OND. Anhe-
donia was rated by using the anticipatory [Temporal Experience Pleasure Scale (TEPS)-ANT]
and consummatory (TEPS-CONS) subscales of theTEPS and two subscales extracted from
the revised Physical Anhedonia Scale (PAS), measuring physical anticipatory (PAS-ANT)
and physical consummatory (PAS-CONS) anhedonias.The Snaith–Hamilton Pleasure Scale
(SHAPS) and the Beck Depression Inventory-II (BDI-II) were also used together with a
subscale extracted from the BDI-II (ENDO-BDI-II) for the diagnosis of endogenomorphic
depression. Statistical analyses were performed on the whole group and on the PD group.
Results: As hypothesized, several anhedonia scores varied with age and gender in the
whole population or in the PD group. On univariate or multivariate analyses, only PAS-
CONS was specific for PD and only SHAPS scores differed between depression subtypes
in the whole population or the PD group.
Conclusion:This study suggests that physical consummatory anhedonia could be specific
to PD subjects.
Keywords: anhedonia, depression, dopamine, Parkinson’s disease
INTRODUCTION
Anhedonia is defined as a lowered ability to experience pleasure.
It is recognized to be a core symptom of major depression and
approximately 30–40% of subjects with Parkinson’s disease (PD)
experience significant depression (1). However, independently of
the presence of depression in PD, anhedonia can be considered
to be a specific mood disorder explained by hypoactivation of the
dopamine reward pathway secondary to the degenerative processes
observed in PD, particularly in the mesolimbic area (2). In PD,
anhedonia is considered as one of the hypodopaminergic symp-
toms, some treatments for PD, especially dopamine agonists, can
induce impulse control disorders (ICD) such as pathologic gam-
bling or hypersexuality, that, in contrast, are characterized by
hyperhedonia.
Anhedonia, as well as other non-motor symptoms of PD, is
underdiagnosed and consequently undertreated (3). It is therefore
surprising that although investigation of anhedonia in PD could
have important clinical and therapeutic consequences, few studies
have been published on this subject.
One of the main unresolved questions is whether or not
the relationship between anhedonia and PD can be completely
explained by the relationship between depression and anhedonia.
This relationship has been extensively examined in the psychiatric
literature. Anhedonia is present in more than two-thirds of all
individuals with major depression (4). Non-major depression is
associated with a low prevalence of anhedonia and the hedonic
capacity may remain intact.
The prevalence of anhedonia in PD ranged from 4.7 to 45.7%
using a cutoff of 3 on the Snaith–Hamilton Pleasure Scale (SHAPS)
(5–12).
A strong association in PD was observed between depression
and anhedonia, but the studies reported discordant results con-
cerning the level of anhedonia in non-depressed PD patients, as
anhedonia appears to be associated with akinesia, apathy, and
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cognitive impairment, but these relationships were not reported
in all studies (5–12).
In major depression, several studies have validated the hypoth-
esis proposed by Klein (13) suggesting the existence of a
subtype of major depression called endogenomorphic depres-
sion characterized by pervasive anhedonia. According to Klein,
endogenomorphic depression is characterized by consumma-
tory anhedonia and appetitive (anticipatory) anhedonia, whereas
non-endogenomorphic depression is characterized exclusively by
appetitive anhedonia. Recently, the distinction between the expe-
riences of pleasure related either to online experience in response
to a specific stimulus (consummatory pleasure) or to future plea-
surable activities (appetitive or anticipatory pleasure) has been
validated by cumulative, cross-discipline evidence (14). According
to Burgdorf and Panksepp (15), there is now converging evidence
to suggest that various regions of the limbic system, especially ven-
tral striatal dopaminergic systems, are involved in an anticipatory
(appetitive) positive affective state. Dopaminergic-independent
mechanisms, mediated by opiate and GABA receptors in the
ventral striatum, amygdala, and orbital frontal cortex, play an
important role in elaborating consummatory positive affective
(i.e., sensory pleasure) states, and various neuropeptides mediate
homeostatic satisfactions.
Several hypotheses were tested in the present study. Firstly, is
one of the various types of anhedonia specific to PD? Secondly,
we tested the hypothesis that, in PD, anticipatory and consumma-
tory anhedonias were associated with non-endogenomorphic and
endogenomorphic depression, respectively. Thirdly, is there a spe-
cific pattern of association in PD between features of the disease
and the various types of anhedonia that explain the discrepancies
reported in the literature?
The aim of this study was therefore to investigate hedonic
deficits in PD by taking into account the limitations of previ-
ous studies. The three previous hypotheses were tested. We used
several rating scales evaluating the various types of anhedonia,
notably the distinction between consummatory and anticipatory
anhedonia. A control group comprising subjects with various non-
PD motor neurologic diseases with control of socio-demographic
variables was used. The relationships between the various types of
anhedonia and depression were examined by taking into account
the non-endogenomorphic/endogenomorphic distinction.
MATERIALS AND METHODS
PATIENTS
The study included 49 patients with idiopathic PD according to
the UKPDSBB (United Kingdom Parkinson’s Disease Brain Bank)
criteria and 40 patients with a non-PD motor neurologic disease
(OND). Participants were consecutively recruited in the Amiens
University Hospital Department of Neurology. All subjects were
outpatients and the study was performed at follow-up visits dur-
ing regular treatment with antiparkinsonian drugs. The study was
approved by our local Ethics Committee and, in accordance with
the Helsinki declaration, each subject signed an informed consent
form before starting the study.
All patients with idiopathic PD or OND were over the age
of 18 and were not demented (Mini-mental State Examination,
MMSE >23). The diagnosis of idiopathic PD was established by
a neurologist specialized in movement disorders (Pierre Krys-
tkowiak). Exclusion criteria were: history of non-neurological
chronic disease, history of psychiatric disorder, or neurologic dis-
ease other than idiopathic PD, non-stabilized dopamine therapy.
The following data were available for PD patients: MMSE, motor
examination (UPDRS part III), Hoehn and Yahr stage, age at
onset, duration of disease, fluctuations (yes or no), and treatment
(l-DOPA, dopamine agonists, entacapone).
The control group comprised 40 patients with the following
motor neurologic diseases: cervical dystonia (N = 17), hemifacial
spasm (N = 8), blepharospasm (N = 7), writer’s cramp (N = 4),
cerebellar ataxia (N = 2), myoclonus (N = 1), and congenital
torticollis (N = 1). As dystonia is considered as basal ganglia
disorder contrary to the diagnoses of the other controls, these
two groups were compared on the socio-demographic, clini-
cal, and psychometrical variables. No significant differences were
found.
RATING SCALES
The subjects of the two groups filled out four questionnaires, three
rating anhedonia and one rating depression.
Consummatory and anticipatory anhedonia were rated using
the Temporal Experience Pleasure Scale (TEPS) and two subscales
extracted from the revised Physical Anhedonia Scale (PAS).
– TEPS: The 18-item Temporal Experience Pleasure Scale (TEPS)
(14) comprises two subscales measuring trait consummatory
pleasure (consummatory subscale of the Temporal Experience
of Pleasure Scale, TEPS-CONS) and trait pleasure in antic-
ipation of future events (anticipatory subscale of the TEPS,
TEPS-ANT). The TEPS-CONS and TEPS-ANT comprise 16
and 10 items, respectively, rated from 1 to 6 with total scores
ranging from 16 to 96 and 10 to 60 for the TEPS-CONS and
TEPS-ANT, respectively. The level of anhedonia is inversely
related to the total score of the rating scales. The psychome-
tric properties of the TEPS have been found to be satisfactory in
various samples of non-clinical and psychiatric patients (14,16).
French versions of these scales, with satisfactory psychometric
properties, were used in this study (17).
– Subscales of the revised PAS (18): several studies (14, 16, 17) in
non-clinical and clinical subjects have reported that the TEPS-
ANT and TEPS-CONS were significantly correlated with the
PAS, whereas the revised Social Anhedonia Scale (SAS) was
only correlated with the TEPS-ANT. Using the university sam-
ple of the French version of the TEPS validation study (17),
we therefore created the PAS anticipatory (PAS-ANT) and PAS
consummatory (PAS-CONS) scales by taking into account the
correlations between the items of the PAS and the TEPS-CONS
or TEPS-ANT scales. Ten items and 16 items were adopted for
the PAS-ANT and PAS-CONS subscales, respectively. The items
of the PAS-ANT and PAS-CONS were: PAS-ANT (5, 9, 18, 19,
23, 25, 48, 56, 59, 61); PAS-CONS (4, 11, 13, 21, 22, 24, 29, 32,
35, 46, 50, 52, 55, 57, 8, 60) using the pages 642–643 of the
publication of the French version of the PAS (19). These two
subscales presented satisfactory psychometric properties (17).
Total scores for the PAS-ANT and PAS-CONS ranged from 0
to 10 and 0 to 16, respectively, and were related to the level of
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anhedonia. PAS-ANT and PAS-CONS rate the anticipatory and
consummatory components of physical anhedonia, respectively.
– SHAPS: The SHAPS (20) is the only rating scale meeting
the criteria of a “suggested” anhedonia scale according to the
Movement Disorder Society (21). The SHAPS is a self-rating
scale comprising 14 items that cover four domains of plea-
sure: interest/pastimes; social interaction; sensory experiences,
and food/drink. High scores represent a reduction of hedonic
tone. A score of three or more allows a categorical definition
of anhedonia (20). The French version of the scale with sat-
isfactory reliability and validity was used (22). In view of the
correlations between the SHAPS and the TEPS-ANT and TEPS-
CONS reported in one study (17), the SHAPS was considered
to be a measure of consummatory anhedonia and anticipatory
anhedonia.
– Contrary to the TEPS, the PAS-ANT and PAS-CONS allowed
to measure the physical and sensorial components of antici-
patory and consummatory anhedonias. The use of the SHAPS
allowed firstly to study the prevalence of anhedonia as cutoff
scores were available and secondly to compare the results of the
present study with these reported in the previous studies.
– BDI-II: Depression was rated using the 21-item Beck Depres-
sion Inventory-II [BDI-II (23). The BDI-II is the 1996 revision
of the classic BDI. The French version of the BDI-II has satis-
factory psychometric properties (24). The total score ranges
from 0 to 63 and higher total scores indicate more severe
depressive symptoms. The following cutoff scores were used to
distinguish non-depressed, moderately depressed, and severely
depressed subjects: 0–11: no depression; 12–28: mild and mod-
erate depression; and 29–63: severe depression. A subscale
(endogenomorphic BDI-II subscale, ENDO-BDI-II) compris-
ing five items (loss of satisfaction, loss of interest in people, loss
of interest in sex, early morning wakening, and loss of appetite)
has also been constructed (25) to allow the diagnoses of endoge-
nous (endogenomorphic) depression. The total score of this
subscale ranges from 0 to 15 and the following cutoff scores
have been defined: no depression (0–3), non-endogenomorphic
depression (4–6), endogenomorphic depression (7–15).
– The following rating scales or interviews were used to evaluate
the clinical features of PD patients: MMSE with scores ranging
from 0 to 30 (worst score= 0; best score= 30); motor score from
the UPDRS (motor part of the Unified PD Rating Scale; worst
score= 108, best score= 0). Hoehn and Yahr stage was used to
rate severity of the disease (worst score= 5; best score= 0).
STATISTICAL ANALYSIS
Firstly, to test the hypothesis that one subtype of anhedonia may
be specific to PD and, secondly, to test the hypothesis of specific
associations between each subtype of anhedonia and depression,
we examined the relationships, for the two groups combined,
between each anhedonia scale and socio-demographic or clini-
cal variables. Univariate and multivariate analyses were performed
using the following variables: group (PD versus OND), gender, age,
level of education, depression severity (BDI score), subtypes of
depression (non-depressed, mild depression, severe depression),
endogenomorphic subtypes of depression (non-depressed, non-
endogenomorphic, endogenomorphic depression). For univariate
analyses, Student’s t tests, analysis of variance (ANOVA), Pearson’s
correlation, and Chi-square analysis were used. Multivariate analy-
ses were performed for each anhedonia scale. Multiple regression
analysis was conducted using the anhedonia scores as dependent
variables and the significant variables identified on univariate
analyses as independent variables. A less conservative p (p< 0.1)
was used for inclusion in multivariate analyses.
Secondly, the relationships between the various types of anhe-
donia and depression were examined in each group according to
the two different subtypes of depression.
Thirdly, the relationships between the various types of anhe-
donia and features of the disease in the PD group were exam-
ined by univariate and multivariate analyses using the follow-
ing variables: gender, age, level of education, depression severity
(BDI score), subtypes of depression (non-depressed, mild depres-
sion, severe depression), endogenomorphic subtypes of depres-
sion (non-depressed, non-endogenomorphic, endogenomorphic
depression), MMSE, motor UPDRS, Hoehn and Yahr stage, age at
onset, duration of disease, fluctuations (yes or no), and treatment
(l-DOPA, dopaminergic agonists, entacapone). Multiple regres-
sions were conducted using the anhedonia scores as dependent
variables and the significant variables identified on univariate
analyses as independent variables. A less conservative p (p< 0.1)
was used for inclusion in multivariate analyses. Statistical tests
were two-tailed with p< 0.05.
RESULTS
The clinical and psychometric characteristics of the two groups
are shown in Table 1.
ENTIRE SAMPLE (TWO GROUPS OF PATIENTS; N = 89)
For the entire sample, the univariate associations between each
anhedonia scale and socio-demographic variables and depression
are shown in Table 2.
Univariate analyses
Several associations between gender or age and anhedonia scales
were observed, the majority of which was not significant. In terms
of the specificity for anhedonia, only PAS-CONS scores were sig-
nificantly different between groups, with higher scores observed
in PD patients compared to controls. A trend toward a signifi-
cant correlation was also observed between age and PAS-CONS
(r = 0.19, p< 0.1).
Concerning the relationship between depression and anhedo-
nia, two anhedonia scales’ (TEPS-CONS and SHAPS) scores were
correlated with BDI-II scores, with values of −0.21 (p< 0.05)
and 0.26 (p< 0.05), respectively. When categorical definitions of
depression were used, only SHAPS scores were correlated with
depression.
Significant differences for SHAPS scores were observed between
non-depressed, mildly depressed, and severely depressed subjects
[F(2, 86)= 4.42, p= 0.015]. Post hoc tests showed that severely
depressed subjects had significantly higher SHAPS scores than
mildly depressed subjects and non-depressed subjects. No signif-
icant difference was observed between mildly depressed subjects
and non-depressed subjects.
Significant differences for SHAPS scores were observed between
non-depressed, non-endogenomorphic, and endogenomorphic
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Table 1 | Comparison between Parkinson’s disease (PD) subjects and
subjects with other neurologic disease (OND).
PD (n=49) OND (n=40) P
Gender 57% males (n=28) 45% males (n=18) 0.25
Age (years) 64.84 (SD=10.84) 60.1 (SD=12.07) 0.06
Level of
educationa (I/II)
22/14/13 13/14/13 0.67
TEPS-ANT 39.37 (SD=6.34) 39.3 (SD=6.65) 0.96
TEPS-CONS 34.65 (SD=6.72) 34.95 (SD=7.44) 0.84
PAS-ANT 2.39 (SD=1.55) 2.27 (SD=1.36) 0.72
PAS-CONS 5.67 (SD=2.19) 4.7 (SD=2.26) 0.041
SHAPS 1.24 (SD=1.53) 0.95 (SD=1.45) 0.36
BDI-II total score 18.51 (SD=8.9) 15 (SD=11.59) 0.11
SHAPS ≥3 18.4% (n=9) 7.5% (n=3) 0.12
Depression
(BDI-II >11)
75.5% (n=37) 50% (n=20) 0.0191
Endogenomorphic
depression
14.3% (n=7) 12.5% (n=5) 0.73
(ENDO-BDI-II >6)
Duration of disease
(years)
7.37 (SD=4.56) 7.2 (SD=5.3) 0.8
Age at onset (years) 56.7 (SD=10.44) 55.5 (SD=9.3) 0.5
MMSE 25.29 (3.27)
UPDRS part III 29.36 (32.16)
Hoehn and Yahr stage 2.25 (0.8)
Fluctuations 67.3% (N =33)
l-DOPA 87.7% (N =43)
Dopamine agonists 63.3% (N =31)
Entacapone 36.7% (N =18)
aLevel of education: I<baccalaureate, II=baccalaureate; III>baccalaureate; bac-
calaureate corresponds to the end of secondary school studies, i.e., 12 years of
accredited education after the age of 6; TEPS, Temporal Experience of Pleasure
Scale; TEPS-ANT, anticipatory subscale of the TEPS; TEPS-CONS, consumma-
tory subscale of the TEPS; PAS, revised Physical Anhedonia Scale; PAS-ANT,
anticipatory subscale of the PAS; PAS-CONS, consummatory subscale of the
PAS; SHAPS, Snaith–Hamilton Pleasure Scale; BDI-II, Beck Depression Inventory-
II; MMSE, Mini-Mental State Examination; fluctuations (Levodopa-related motor
complications); 1p<0.05.
depressed subjects [F(2, 86)= 3.1, p= 0.05]. Post hoc tests showed
that endogenomorphic depressed subjects had significantly higher
SHAPS scores than non-endogenomorphic depressed subjects and
non-depressed subjects. No significant difference was observed
between non-endogenomorphic depressed subjects and non-
depressed subjects.
Multivariate analyses
Multiple regression analysis was performed on the PAS-CONS
scale, using the PAS-CONS as dependent variable and the
group (PD versus Controls) and age as independent variables or
predictors.
A significant association was observed [F(2, 86)= 4.89,
p< 0.01] for the two predictors. t values for group and
age were t (86)= 2.54, p= 0.013 and t (86)= 2.31, p= 0.023),
respectively.
RELATIONSHIP BETWEEN ANHEDONIA AND DEPRESSION IN THE OND
GROUP
Successive ANOVAs were performed using each anhedonia scale as
dependent variable and each subtype of depression as independent
variable. No significant association was observed between any of
the anhedonia scales and gender, age, or level of education. None
of these socio-demographic variables were therefore introduced
into ANOVA as confounding variables.
Only one ANOVA was significant for TEPS-ANT [F(2,
37)= 3.81, P = 0.03]. Post hoc tests revealed that non-
endogenomorphic depressed subjects had significant lower TEPS-
ANT scores (i.e., were more severely anhedonic) than non-
depressed subjects.
PARKINSON’S DISEASE GROUP
Univariate associations between each anhedonia scale and socio-
demographic variables, depression and characteristics of the dis-
ease in the PD group are shown in Table 2. Twelve significant
differences were observed, with a trend to significance for four
values.
Univariate analyses
Analysis of socio-demographic variables showed that age was
negatively associated with PAS-ANT, PAS-CONS, and SHAPS
(r =−0.23, p< 0.1, −0.34, p< 0.05, −0.43, p< 0.05, respec-
tively). Higher scores on these scales were observed in the youngest
PD subjects. Higher PAS-ANT scores were observed in males
compared to females (p< 0.09).
Analysis of clinical variables showed that age at onset was neg-
atively associated with PAS-CONS, PAS-ANT, and SHAPS and
duration of disease was negatively associated with anhedonia mea-
sured by TEPS-CONS (r = 0.45, p< 0.05) and SHAPS (r =−0.25
p< 0.05).
Higher stages of disease, as rated by Hoehn and Yahr stage,
were associated with PAS-CONS (r =−0.32, p< 0.05) and
TEPS-ANT (r = 0.28, p< 0.05). Motor impairment, as evalu-
ated by the UPDR-III subscale, was associated with TEPS-ANT
(r = 0.29, p< 0.05). MMSE score was associated with TEPS-
CONS (r = 0.29, p< 0.05) and subjects who received entacapone
had lower PAS-ANT scores than PD subjects not treated with this
molecule.
Depression subtypes were associated with SHAPS scores.
A significant difference was observed according to subtype
of depression, classified as no depression, mild depression,
and severe depression [F(2, 46)= 4.21, p< 0.021]. Post hoc
tests showed that severely depressed subjects had significantly
higher SHAPS scores than mildly depressed subjects, while
the SHAPS scores of non-depressed subjects were not signif-
icantly different from those of mildly depressed subjects or
severely depressed subjects. Analysis of subtypes of depression
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Table 2 | Univariate associations between socio-demographic variables, depression, and anhedonia scales for the entire sample (N =89) or for
the Parkinson’ group (N =49).
TEPS-ANT TEPS-CONS PAS-ANT PAS-CONS SHAPS
89 49 89 49 89 49 89 49 89 49
Gender 0.07 0.09
Age (years) 0.1 0.1 0.05 0.05
BDI-II total score 0.05 0.05
Group (PD/C)a 0.04
Depression subtypeb 0.015 0.02
Endogenomorphic subtypec 0.05 0.1
MMSE 0.05
UPDRS-III 0.05
Hoehn and Yahr stage 0.05 0.05
Age of onset 0.05 0.05 0.05
Duration 0.05 0.05
Entacapone 0.1
TEPS,Temporal Experience of Pleasure Scale;TEPS-ANT, anticipatory subscale of theTEPS;TEPS-CONS, consummatory subscale of theTEPS; PAS, revised Physical
Anhedonia Scale; PAS-ANT, anticipatory subscale of the PAS; PAS-CONS, consummatory subscale of the PAS; SHAPS, Snaith–Hamilton Pleasure Scale; BDI-II, Beck
Depression Inventory-II.
aGroup (PD, Parkinson’s disease group; OND, non-Parkinson’s motor neurologic disease),
b(non-depressed BDI-II: 0–11, mild depressed: BDI-II: 12–28, severely depressed: BDI-II: 29–63);
cendogenomorphic subtypes using endogenomorphic subscale of the BDI-II (ENDO-BDI-II): no depression (ENDO-BDI-II: 0–3), non-endogenomorphic depression
(ENDO-BDI-II: 4–6), endogenomorphic depression (ENDO-BDI-II: 7–15).
Bold font denotes p<0.05.
according to no depression, non-endogenomorphic depres-
sion, and endogenomorphic depression showed a trend toward
significance [F(2, 46)= 2.46, p< 0.1]. Post hoc tests revealed
a trend for endogenomorphic depressed subjects to have sig-
nificantly higher SHAPS scores than non-endogenomorphic
depressed subjects. The SHAPS scores of non-depressed sub-
jects were not significant different from those of non-
endogenomorphic depressed subjects or severe endogenomorphic
depressed subjects.
Multivariate analyses
Duration of disease and MMSE scores were introduced into mul-
tiple regression analysis of the TEPS-CONS and no significant
associations were observed. Hoehn and Yahr stage and UPDR-III
scores were introduced into multiple regression analysis of the
TEPS-ANT and no significant associations were observed. Age,
age at onset, and Hoehn and Yahr stage were introduced into the
regression analysis of the PAS-CONS. A significant association was
observed [F(3, 45)= 10.6, p< 0.0003]. Among the three predic-
tors, only age was significant [t (45)= 3.14, p< 0.0006] explaining
56% of the variance.
Four variables were entered into the regression analysis of the
PAS-ANT: gender, age, age at onset, and entacapone. No significant
association was observed.
Two multiple regression analyses were performed for the
SHAPS. The first multiple regression analysis included age, age at
onset, and depression subtype (no depression, mild depression,
severe depression) as predictors and no significant association
was observed. The second multiple regression analysis includes
age, age at onset, and depression subtype (no depression, no
endogenomorphic depression, endogenomorphic depression) as
predictors and no significant association was observed.
DISCUSSION
This is the first study to examine the various components of
anhedonia in Parkinsonian subjects, especially the distinction
between anticipatory and consummatory anhedonia. This study
was also characterized by three important points not taken into
account in previous studies. Firstly, the control group was com-
posed of patients with motor non-PD neurologic disease. The use
of this type of control group allowed control of motor impair-
ment as a potential bias that could lead to anhedonia secondary
to reactive depression. Secondly, socio-demographic character-
istics (age, gender, level of education, inpatient/outpatient sta-
tus) were statistically controlled. Thirdly, the distinction between
endogenomorphic and non-endogenomorphic depression was
taken into account.
The control group of the present study was composed of
patients presenting dystonia, cerebellar, or peripheral nervous sys-
tem diseases. Generally, dystonia is considered as basal ganglia
disorder and abnormalities in dopaminergic activity have been
proposed. The inclusion of such patients in the control group
might have influenced the results. This potential bias has been
discarded as the patients with dystonia did not differ on the socio-
demographic, clinical, and psychometrical variables comparatively
with the other controls.
It is important to note that the OND group allowed the control
of motor impairment and its consequences as reactive depression.
Among the eight previous published studies (5–12), any study has
used non-PD neurological patients as controls.
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OUR FIRST HYPOTHESIS TESTED WHETHER ONE PARTICULAR TYPE OF
ANHEDONIA SPECIFICALLY CHARACTERIZED PD SUBJECTS
Univariate and multivariate analyses on the two samples showed
that physical consummatory anhedonia was characteristic of PD
subjects. This effect is independent of age and depression, as
demonstrated by multivariate analyses. This result was unex-
pected, as we had initially hypothesized that higher levels of antic-
ipatory anhedonia would be observed in PD subjects compared to
subjects with non-PD motor neurologic disease. Consummatory
anhedonia, as measured by decreased sucrose preference in rats,
requires combined depletion of all three monoamines (serotonin,
dopamine, noradrenaline) (26). Physical consummatory anhedo-
nia in PD could therefore be related and explained by dopamine,
noradrenaline, and serotonin deficiency. If these high levels of con-
summatory anhedonia are confirmed by other studies, agonists
of these three neurotransmitters could therefore be used to treat
anhedonia in PD subjects. Another explanation could be related
with the use of a control group including subjects with dystonia.
In this disorder, dopaminergic deficiency has been involved sug-
gesting that the level of anticipatory anhedonia could be the same
between the PD and control groups.
The prevalence of anhedonia using the SHAPS cutoff in this
study did not differ between the two groups and was 18.4% in the
PD group. This value was similar to those reported in previous
studies, ranging from 4.7% (12) to 45.7% (7).
The second hypothesis tested the relationship between anhedo-
nia and depression and especially the association between consum-
matory or anticipatory anhedonia and non-endogenomorphic or
endogenomorphic forms of depression.
Firstly, only the SHAPS was significantly associated with this
depression subtype. This association was observed for the entire
sample and in PD subjects. Endogenomorphic depressed subjects
had higher SHAPS scores than non-endogenomorphic depressed
subjects. As the SHAPS score rates consummatory and antici-
patory pleasure, the present study did not confirm our a pri-
ori hypothesis of a relationship between anticipatory anhedonia
and non-endogenomorphic depression and between consum-
matory anhedonia and endogenomorphic depression. However,
our results were compatible with the hypothesis formulated by
Klein (13). This author suggested that the defect in the con-
summatory pleasure system was always accompanied by a defect
in the appetitive (anticipatory) pleasure system. Secondly, Klein
suggested that a defect in the consummatory system always pro-
duced autonomous or endogenomorphic depression. The rela-
tionships between consummatory and anticipatory anhedonia and
non-endogenomorphic versus endogenomorphic depression are
therefore not specific to PD (27).
Moreover, for the entire sample and for PD subjects, only the
SHAPS was significantly associated with depression subtype, clas-
sified as no depression, mild depression, and severe depression.
Severely depressed subjects had significantly higher SHAPS scores
than mildly depressed subjects. The results of this study therefore
show that the relationship between depression and anhedonia is
not specific to PD.
Secondly, only severely depressed or endogenomorphic
depressed subjects had high levels of anhedonia compared to
non-endogenomorphic depressed or mildly depressed subjects.
These results suggest that mildly depressed subjects with motor
(PD or other) neurologic diseases were not characterized by high
levels of anhedonia. Moreover, these results were observed for con-
summatory and anticipatory anhedonia rated together. Several
studies using the SHAPS or PAS scales have reported either no
relationship between anhedonia and depression (6) or higher lev-
els of anhedonia in depressed PD subjects than in controls (7, 9).
However, in these studies, the authors did not distinguish between
non-depressed, mildly depressed, and severely depressed subjects.
A recent study conducted in 254 PD subjects compared SHAPS
scores between non-depressed PD subjects, mildly depressed sub-
jects, and severely depressed subjects (12), in whom depression
was diagnosed according to DSM-IV criteria. Severely depressed
PD subjects had higher SHAPS scores than the other two groups.
These authors also reported significant correlations between the
SHAPS and BDI-II scores only in the severely depressed and non-
depressed PD groups and concluded that anhedonia, as rated by
the SHAPS, was correlated with the severity of depression in PD
subjects with either severe depression or no depression.
We therefore propose that high levels of consummatory and
anticipatory anhedonia, as rated by the SHAPS, could character-
ize endogenomorphic or severely depressed PD subjects compared
to non-endogenomorphic or mildly depressed PD subjects. How-
ever, this relationship was also observed in patients with non-PD
motor neurologic disease. We did not confirm the results of the
study by Spalletta et al. (12) that suggested that non-depressed PD
subjects were characterized by anhedonia.
Relationships between SHAPS and depression have been
explored in healthy or psychiatric subjects. Several studies, using
the BDI, reported significant correlations with higher values in
psychiatric subjects than in healthy subjects (28, 29).
The third hypothesis examined the relationships between fea-
tures of the disease in the PD group and the various types of
anhedonia in order to detect a specific pattern of associations,
especially explaining the discrepancies reported in the literature.
Univariate analyses revealed several significant or non-significant
associations between anhedonia scales and clinical variables, but
none of the multivariate analyses performed for each anhedonia
scale were significant. The present study therefore failed to demon-
strate a particular profile between each anhedonia scale and clinical
variables.
Two studies using the SHAPS and one study using the TEPS-
ANT and TEPS-CONS did not observe any relationship between
anhedonia and age at onset or duration of disease (10, 11). One
study did not report any relationship between age at onset, dura-
tion of disease, Hoehn and Yahr stages, and SHAPS scores (11)
and Isella et al. (6), using the PAS scale, did not observe any
significant correlation between the scale and age, UPDR-III, or
disease duration. Moreover, no relationship has been reported
between UPDRS-III, Hoehn and Yahr stage, or disease duration
and TEPS-ANT and TEPS-CONS (11).
No relationship has been reported between MMSE scores and
SHAPS (10) or TEPS-CONS or TEPS-ANT (11). One study found
an association between entacapone and more severe anhedonia, as
rated by the SHAPS (10).
It is noteworthy that all but one (10) of the previous studies
reporting significant associations between anhedonia scales and
clinical characteristics of the disease did not control for socio-
demographic variables and the other significant clinical variables
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by means of multivariate analyses such as multiple regression
analysis.
In the present study, multivariate analyses did not provide
any significant results except for the PAS-CONS. Age was signif-
icantly associated with consummatory physical anhedonia (30).
Young PD subjects were characterized by high levels of this type
of anhedonia.
This study has a number of limitations. Firstly, the small sam-
ple sizes may explain the negative results due to the low power
of statistical tests. Secondly, PD subjects were consecutive outpa-
tients presenting various stages of PD. PD subjects represented a
heterogeneous sample that may have presented various levels of
hedonic deficits.
CONCLUSION
Anhedonia in PD could be explained by socio-demographic vari-
ables, depression, and characteristics of the disease. There are not
currently accepted treatment strategies for the different anhedo-
nias. The present study suggests, for the first time, that physical
consummatory anhedonia could be specific to PD in contrast with
anticipatory anhedonia.
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